Biotech RadarJobs updated

COMPANY

Ocugen

HQ: Malvern, PA source · ocugen.com ↗ · Mid-Atlantic

Clinical Phase 3

Location: Malvern, PA · source · Oct 14, 2026

Profile checked Oct 10, 2026

Keywords: Retinitis Pigmentosa COVID-19 Dry Eye Dry Age-related Macular Degeneration Geographic Atrophy Stargardt Disease Leber Congenital Amaurosis Center Involved Diabetic Macular Edema Diabetic Macular Edema Graft Versus Host Disease Ocular Surface Disease oGVHD Ocular Graft vs Host Disease Lubricant Eye Drops Ophthalmic Solutions Graft vs Host Disease Brimonidine OCU410 BBV152 OCU400 Sub-Retinal Administration of OCU400-301 OCU410ST OCU200

$42.5MRaised (2 yrs)12Trials (company is sponsor)

Timeline

  1. Trial start 3: Phase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic Atrophy Secondary to Dry AMD source ↗
  2. Debt Debt: $115M (not counted as a raise), announced May 5, 2026. Source: company release on GlobeNewswire. source ↗
  3. Raise Follow-on offering — Registered direct: $22.5M (total, as published), announced Jan 23, 2026. Source: company release on GlobeNewswire. source ↗
  4. Raise Follow-on offering — Registered direct: $20M (total, as published), announced Aug 12, 2025. Source: company release on GlobeNewswire. source ↗
  5. Debt Debt: $30M (not counted as a raise), announced Nov 7, 2024. Source: SEC filing. source ↗
  6. Trial start 3: A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa source ↗
  7. Trial start I: Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME) source ↗
  8. Trial start 2: A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease source ↗
  9. Trial start Phase 1/Phase 2: Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy source ↗
  10. Trial start Phase 2/Phase 3: Immuno-bridging and Broadening Study of a Whole, Inactivated COVID-19 Vaccine BBV152 in Healthy Adults source ↗
  11. Trial start Phase 1/Phase 2: Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis source ↗
  12. Trial start Phase 3: Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease source ↗
  13. Trial start Phase 3: Study of Brimonidine Tartrate Nanoemulsion Eye Drop Solution in the Treatment of Dry Eye Disease (DED) source ↗
  14. Trial start Phase 2: Dry Eye Disease Study With Brimonidine source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $42.5M · Debt: $145.0M. Last 2 years.

Clinical trials (lead sponsor) 12

RecordTitlePhaseStatusStartPrimary completion
NCT06574997Expanded Access Program for RP in AdultsNot listedNo longer availableNot listedNot listed
NCT07770828Phase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic Atrophy Secondary to Dry AMD3RecruitingAug 11, 2026Jul 30, 2028 (estimated)
NCT06018558Study to Assess the Safety and Efficacy of OCU410 for Geographic AtrophyPhase 1/Phase 2Active, not recruitingFeb 23, 2023Feb 3, 2026 (actual)
NCT06388200A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa3Active, not recruitingJun 18, 2024Feb 12, 2027 (estimated)
NCT05956626A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease2Active, not recruitingAug 25, 2023Sep 28, 2026 (estimated)
NCT05203939Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital AmaurosisPhase 1/Phase 2Active, not recruitingJan 24, 20222027-03 (estimated)
NCT05802329Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)IRecruitingJan 13, 2024Jul 31, 2026 (estimated)
NCT05258669Immuno-bridging and Broadening Study of a Whole, Inactivated COVID-19 Vaccine BBV152 in Healthy AdultsPhase 2/Phase 3Unknown status (ClinicalTrials.gov)Feb 20, 2022Sep 1, 2023 (estimated)
NCT05541289Expanded Access Program of Whole, Inactivated COVID-19 Vaccine COVAXIN™ (BBV152) in Adults Aged 18 Years and OlderNot listedNo longer availableNot listedNot listed
NCT03785340Study of Brimonidine Tartrate Nanoemulsion Eye Drop Solution in the Treatment of Dry Eye Disease (DED)Phase 3CompletedDec 3, 2018Feb 25, 2019 (actual)
NCT03591874Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host DiseasePhase 3TerminatedDec 23, 2018Apr 30, 2020 (actual)
NCT03418727Dry Eye Disease Study With BrimonidinePhase 2CompletedSep 6, 2017Mar 29, 2018 (actual)
Feedback